NASDAQ:ERNA Ernexa Therapeutics (ERNA) Stock Price, News & Analysis $3.99 +0.25 (+6.68%) Closing price 03:58 PM EasternExtended Trading$4.00 +0.01 (+0.38%) As of 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Ernexa Therapeutics Stock (NASDAQ:ERNA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Ernexa Therapeutics alerts:Sign Up Key Stats Today's Range$3.80▼$4.2550-Day Range$3.69▼$8.1052-Week Range$3.18▼$100.46Volume76,360 shsAverage Volume31,262 shsMarket Capitalization$4.67 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts. Read More Ernexa Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks9th Percentile Overall ScoreERNA MarketRank™: Ernexa Therapeutics scored higher than 9% of companies evaluated by MarketBeat, and ranked 834th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingErnexa Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageErnexa Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Ernexa Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Ernexa Therapeutics is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ernexa Therapeutics is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioErnexa Therapeutics has a P/B Ratio of 0.52. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Ernexa Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.70% of the float of Ernexa Therapeutics has been sold short.Short Interest Ratio / Days to CoverErnexa Therapeutics has a short interest ratio ("days to cover") of 0.23, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Ernexa Therapeutics has recently increased by 25.42%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldErnexa Therapeutics does not currently pay a dividend.Dividend GrowthErnexa Therapeutics does not have a long track record of dividend growth. News and Social Media0.9 / 5News Sentiment-0.50 News SentimentErnexa Therapeutics has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Ernexa Therapeutics this week, compared to 1 article on an average week. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Ernexa Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders4.49% of the stock of Ernexa Therapeutics is held by insiders.Percentage Held by Institutions70.55% of the stock of Ernexa Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ernexa Therapeutics' insider trading history. Receive ERNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ernexa Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ERNA Stock News HeadlinesEterna Therapeutics Implements 1-for-25 Reverse Stock SplitMay 4 at 4:51 PM | tipranks.comErnexa Therapeutics Announces 1-for-25 Reverse Stock SplitApril 30, 2026 | globenewswire.comThe Iran War Just Broke the Gold MarketThe Iran war isn't just a geopolitical event. It's a financial one. Within hours of the strikes, oil surged… Defense stocks exploded…And gold ripped past $5,000.May 5 at 1:00 AM | Behind the Markets (Ad)Ernexa Therapeutics Incorporation Registered ShsApril 19, 2026 | markets.businessinsider.comErnexa Therapeutics Inc.April 2, 2026 | edition.cnn.comErnexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026March 31, 2026 | globenewswire.comEterna Therapeutics Faces Nasdaq Delisting Risk After NoticeMarch 20, 2026 | tipranks.comEterna Therapeutics Updates Investor Presentation, Highlights Web DisclosureFebruary 26, 2026 | tipranks.comSee More Headlines ERNA Stock Analysis - Frequently Asked Questions How have ERNA shares performed this year? Ernexa Therapeutics' stock was trading at $30.00 on January 1st, 2026. Since then, ERNA shares have decreased by 86.7% and is now trading at $3.99. How were Ernexa Therapeutics' earnings last quarter? Ernexa Therapeutics Inc. (NASDAQ:ERNA) issued its earnings results on Wednesday, August, 13th. The company reported ($15.25) earnings per share (EPS) for the quarter. When did Ernexa Therapeutics' stock split? Ernexa Therapeutics's stock reverse split before market open on Monday, May 4th 2026.The 1-25 reverse split was announced on Thursday, April 30th 2026. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 1st 2026. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of Ernexa Therapeutics? Shares of ERNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ernexa Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ernexa Therapeutics investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), AST SpaceMobile (ASTS), NIO (NIO), Bakkt (BKKT) and Company Calendar Last Earnings8/13/2025Today5/05/2026Next Earnings (Estimated)5/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (13m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 ERNA's financial health is in the Red zone, according to TradeSmith. ERNA has been in this zone for over 13 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ERNA CIK748592 Webwww.brooklynitx.com Phone(212) 582-1199Fax760-438-3505Employees10Year Founded1953Profitability EPS (Trailing Twelve Months)($3.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$14.08 million Net MarginsN/A Pretax Margin-1,831,114.25% Return on Equity-1,262.77% Return on Assets-228.54% Debt Debt-to-Equity RatioN/A Current Ratio1.01 Quick Ratio1.01 Sales & Book Value Annual Sales$580 thousand Price / Sales8.05 Cash FlowN/A Price / Cash FlowN/A Book Value$7.64 per share Price / Book0.52Miscellaneous Outstanding Shares1,170,000Free Float1,114,000Market Cap$4.67 million OptionableNo Data Beta1.88 Social Links 7 Stocks to Buy Before SpaceX Goes PublicSpaceX has quietly filed to go public later this year. Ahead of what's expected to be the largest IPO of all time, there are seven space stocks that you can buy today that are positioned to benefit from accelerating space commercialization in 2026. These seven companies are shaping the next phase of the space economy—from launch leaders and satellite networks to data, defense, and in-space infrastructure.Get This Free Report This page (NASDAQ:ERNA) was last updated on 5/5/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSell 99% of Your Stocks, Do THIS Instead…Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...The Oxford Club | SponsoredTrade this between 9:30 and 10:45 am ESTThe first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...Base Camp Trading | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredElon Unveils AI Passive Income Stream for Millions of AmericansDuring Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ernexa Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ernexa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
